Hemophilia is a disease comprising a group of genetic disorders which generate specific deficiencies of certain clotting factors, which affects greatly the quality of life of sufferers and generates significant costs for the health system. Inhibitors make the hemophilia treatment less effective when compared with patients who do not experience them. Since inhibitors are a high-cost treatment impacting the health budget, the current economic evaluation aims to evaluate the impact of treating patients with hemophilia and inhibitors.
A cost minimization analysis of activated prothrombin complex concentrate (aPCC) was developed against recombinant activated factor VII (rFVIIa) in prophylactic, surgical and on demand treatment for patients with hemophilia A and B with inhibitors in Colombia, from the perspective of the third payer. Costs: These include hospital services (procedures, hospitalization, laboratory tests, imaging and consultations) to treat bleeding and medicines to the ISS costs were increased by 30% because of inflation. In addition, the estimation of the use of services to treat patients with the disease was held in the database of a health care provider which represents 15% of the total members of the health system in Colombia and it was used to extrapolate the use of services for an average patient nationwide. All costs are showed in USD with the year average exchange rate of 2015. The international literature suggests that both products are similar in terms of their effectiveness in treatment on demand. Prophylactic use of activated prothrombin complex concentrate suggests a higher effectiveness as well as in surgery since aPCC has a longer average half life which means less use of this factor compared to rFVIIa (Table 1 and 2). On demand treatment in the use of rFVIIa per patient, involve an additional cost of USD $17,937 compared to aPCC with 28.7 annual bleeding episodes (same for both technologies) (Figure 1) . For prophylactic scenario, the use of rFVIIa generates additional costs of 61.3% compared to the treatment costs with aPCC ( Figure 2 ).
Figure 2. Total rFVIIa and aPCC prophylaxis treatment costs
On short-term surgery scenario the use of rFVIIa is 27.2% more expensive than aPCC (Table 3) .
It has been shown similar efficacy for both technologies on-demand, and an apparent advantage of the activated prothrombin complex concentrate due to its prolonged effect in the human body in the case of prophylaxis. The cost minimization model showed a difference in the cost of these technologies in favor of the aPCC for three scenarios of analysis. 
